Brokerages predict that Crispr Therapeutics AG (NASDAQ:CRSP) will report earnings of ($0.95) per share for the current quarter, according to Zacks. Four analysts have made estimates for Crispr Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.78) and the lowest estimate coming in at ($1.09). Crispr Therapeutics posted earnings of ($1.07) per share during the same quarter last year, which would suggest a positive year over year growth rate of 11.2%. The firm is expected to announce its next earnings results on Wednesday, November 6th.
According to Zacks, analysts expect that Crispr Therapeutics will report full-year earnings of ($3.85) per share for the current fiscal year, with EPS estimates ranging from ($4.22) to ($3.37). For the next fiscal year, analysts expect that the business will report earnings of ($4.04) per share, with EPS estimates ranging from ($5.59) to ($2.94). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, July 29th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.84). Crispr Therapeutics had a negative return on equity of 51.49% and a negative net margin of 15,136.56%. The company had revenue of $0.32 million during the quarter, compared to the consensus estimate of $47.57 million. During the same quarter last year, the firm earned ($0.82) EPS. The business’s revenue for the quarter was down 70.8% on a year-over-year basis.
CRSP stock traded down $1.02 during trading on Thursday, hitting $39.03. The company had a trading volume of 22,154 shares, compared to its average volume of 521,656. The company has a quick ratio of 13.96, a current ratio of 13.96 and a debt-to-equity ratio of 0.10. The firm has a 50-day moving average price of $42.84 and a 200-day moving average price of $43.37. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $53.90. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -11.34 and a beta of 3.11.
Several institutional investors have recently modified their holdings of CRSP. Nikko Asset Management Americas Inc. raised its position in shares of Crispr Therapeutics by 324.3% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock valued at $88,143,000 after acquiring an additional 1,430,364 shares during the last quarter. ARK Investment Management LLC raised its position in shares of Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after acquiring an additional 701,332 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after acquiring an additional 121,176 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after acquiring an additional 116,540 shares during the last quarter. Finally, Balyasny Asset Management LLC bought a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at $5,165,000. Institutional investors own 50.23% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Blockchain
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.